Home » Newsletters » BioWorld Science

BioWorld Science

May 7, 2007

View Archived Issues

Trials assessing the efficacy of drugs for restless legs syndrome

Preclinical activity of the novel Aurora kinase inhibitor AZD-1152 profiled at the AACR meeting

Novel antiinflammatory agents disclosed in recent patents

Effects of NGX-4010 assessed in HIV-associated distal sensory polyneuropathy

New preclinical data on GSK-923295 reported by GSK and Cytokinetics

Recent patent from Astellas describes novel xanthine oxidase inhibitors

Recent patents disclose new therapeutic agents for anxiety and depression

Preclinical findings on the anti-DR5 agonist antibody LBY-135 reported by Novartis

Potent antitumor and antiangiogenic activity of LP-261 alone or in combination with bevacizumab

Platencin shows antibiotic activity in vivo via inhibition of fatty acid biosynthesis

Purdue Research Foundation licenses flu vaccine candidate to PaxVax

CyDex licenses Captisol enabling technology to Proteolix

Second phase III study begins for OPT-80 in CDAD

Sapacitabine studied in new phase II trial for advanced CTCL

Iplex demonstrates efficacy in HARS

NGD-4715 for obesity completes first-in-man study

Study establishes proof of concept for PRO-140 as antiretroviral agent

Oral cethromycin 100% protective against lethal dose of inhaled anthrax

A novel SIRT1 activator from Sirtris shows neuroprotective effects in optic neuritis in vivo

In vivo antiangiogenic activity of Immusol's new compound, IMS-2186

6R-BH4 enters phase IIa study for sickle cell disease

Treatment complete in phase III study of TH-9507 in HIV-associated lipodystrophy

Expression Genetics receives grant for development of EGEN-001 in ovarian cancer

PrimoVax study of GV-1001 cleared to open in U.S.

Quest advances SL-052 for prostate cancer in preclinical testing

Pivotal trials begin for EOquin in noninvasive bladder cancer

Lux receives Canadian clearance for phase II/III trials of LX-211 in uveitis

IND clearance for study of allogeneic adult stem cells in heart attack patients

Vyvanse receives DEA schedule classification

Ista receives non approvable letter for T-Pred

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...